|
|
|
| Expert consensus on high-dose vitamin C therapy for Cancer 2024 |
| 1Rao Benqiang,1Wang Shiwan,1Shi Hanping,1Qu Jinxiu,1Lu Shuai,1Wang Bing,1He Jia,1Zhao Yuan,2Tang Huazhen,1Wang Lin,1Wang Xin,1Zhang Zhanzhi,1Chen Yongbing ,1Zhu Qiankun ,1Zhang Xiaowei |
| 1Center for Oncology Nutrition and Metabolism Beijing Shijitan Hospital Capital Medical University / Key Laboratory of Cancer FSMP
for State Market Regulation Beijing 100038 China
2Department of General Surgery Beijing Tiantan Hospital Capital Medical
University Beijing 100070 China Chinese Society of Nutritional Oncology CSNO Specialized Committee of Chinese and Western
Integrated Tumor Control Drugs of China Anti Cancer Association Nutrition Metabolism Branch of Chinese Aging Well Association |
|
|
|
|
Abstract The efficacy of high - dose vitamin C HDVC treatment for tumors is fragile and requires precise and intensified
treatment. However there is not only an absence of standardized therapeutic schedule of HDVC for cancers but also a lack of
high-quality guidelines for precise and intensive treatment of HDVC for tumors which seriously affects the therapeutic effect and
clinical application of HDVC. Based on in-depth discussions on the anti-tumor mechanisms and the pharmacokinetic characteristics of
of HDVC experts with rich experience in the Nutrition Therapy Professional Committee of China Anti - Cancer Association the
Research Committee of New Anti-Cancer Drugs for Chinese and Western Integrated Tumor Control and the Nutrition Metabolism Branch
of China Elderly Care Association have reached a consensus on the indications and contraindications of HDVC clinical advantage
administration the prevention and treatment of side effects the sensitivity and precision treatment of metabolic molecular phenotype
the intensive treatment strategy and efficacy monitoring. This consensus will help improve the the standardization and efficacy of of high
dose vitamin C treatment against cancer.
|
|
Received: 01 December 2023
|
|
|
|
|
|
|
